Difference between revisions of "Editing test page"
Jump to navigation
Jump to search
m |
|||
| Line 13: | Line 13: | ||
|2019-02-15 to 2020-12-10 | |2019-02-15 to 2020-12-10 | ||
|style="background-color:#1a9851"|Phase 3 (C) | |style="background-color:#1a9851"|Phase 3 (C) | ||
| − | |[[#Carboplatin. | + | |1a. [[#Carboplatin.2C_Durvalumab.2C_RT_999|Carboplatin, Durvalumab, RT]]<br>1b. [[#Cisplatin.2C_Durvalumab.2C_RT_999|Cisplatin, Durvalumab, RT]] |
| style="background-color:#ffffbf" |Did not meet primary endpoint of PFS | | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS | ||
|- | |- | ||
Revision as of 13:30, 4 December 2023
Carboplatin & RT
Carboplatin & RT: Carboplatin & Radiation Therapy
Regimen variant #1, weekly carboplatin
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Monk et al. 2023 (CALLA) | 2019-02-15 to 2020-12-10 | Phase 3 (C) | 1a. Carboplatin, Durvalumab, RT 1b. Cisplatin, Durvalumab, RT |
Did not meet primary endpoint of PFS |
Chemotherapy
- Carboplatin (Paraplatin) AUC 2 IV once per day on days 1, 8, 15, 22, 29
Radiotherapy
- Concurrent radiation therapy, 1.8 Gy per fraction on days 1 to 5, 8 to 12, 15 to 19, 22 to 26, 29 to 33 (45 Gy total in 25 fractions)
5-week course
Subsequent treatment
- Brachytherapy